Controlling the carcinoid syndrome.
- 12 November 1988
- Vol. 297 (6658) , 1213-1214
- https://doi.org/10.1136/bmj.297.6658.1213
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- The effects of the 5‐hydroxytryptamine (5HT3) receptor antagonist ICS 205‐930 in the carcinoid syndromeAlimentary Pharmacology & Therapeutics, 1988
- Carcinoid tumors: CT and I-131 meta-iodo-benzylguanidine scintigraphy.Radiology, 1987
- Metastatic carcinoid tumors and the carcinoid syndrome: A selective review of chemotherapy and hormonal therapyThe American Journal of Medicine, 1986
- Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamineNeuropharmacology, 1986
- Carcinoid syndrome. Surgical management.1986
- Ketanserin versus Placebo in Carcinoid Syndrome: A Clinical Controlled TrialScandinavian Journal of Gastroenterology, 1986
- Role of hepatic arterial embolisation in the carcinoid syndrome.BMJ, 1983
- TREATMENT OF CARCINOID LIVER METASTASES BY HEPATIC-ARTERY EMBOLISATIONThe Lancet, 1977
- Present Experiences with Hepatic Dearterialization in Liver NeoplasmPublished by S. Karger AG ,1973
- Studies on Several Possible Antiserotonin Compounds in a Patient with the Functioning Carcinoid SyndromeAnnals of Internal Medicine, 1962